Largest pharmaceuticals by earnings
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Johnson & Johnson leads the 61 pharmaceuticals ranked by earnings, at CA$38.4B, ahead of Eli Lilly (CA$29.5B) and Merck & Co (CA$26.1B). Figures as of 18 Nov 2026, 14:31 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 61
- First
- Johnson & JohnsonCA$38.4B
- Median
- CA$84.5M
- Combined market value
- CA$7.32T
- Countries
- 10
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Earnings ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | CA$38.4B | CA$951.2B | CA$395.14 | 1.00% down | 38% up | ||
| 2 | Eli LillyLLY · Health Care | CA$29.5B | CA$1.79T | CA$2,014.01 | 0.60% down | 35% up | ||
| 3 | Merck & CoMRK · Health Care | CA$26.1B | CA$498.8B | CA$202.33 | 1.44% down | 51% up | ||
| 4 | Novo NordiskNVO · Health Care | CA$21.8B | CA$253.3B | CA$57.47 | 1.36% down | 17% down | ||
| 5 | NovartisNVS · Health Care | CA$20B | CA$424.4B | CA$224.71 | 1.37% down | 25% up | ||
| 6 | AstraZenecaAZN · Health Care | CA$14.6B | CA$399.4B | CA$257.49 | 1.28% down | 2% up | ||
| 7 | SanofiSNY · Health Care | CA$12.4B | CA$162.6B | CA$67.72 | 0.47% down | 4% down | ||
| 8 | PfizerPFE · Health Care | CA$11.1B | CA$230.7B | CA$40.47 | 0.66% down | 14% up | ||
| 9 | GSKGSK · Health Care | CA$10.9B | CA$140.4B | CA$70.03 | 0.62% down | 6% up | ||
| 10 | Bristol-Myers SquibbBMY · Health Care | CA$10.1B | CA$177.7B | CA$86.95 | 1.04% down | 34% up | ||
| 11 | Abbott LaboratoriesABT · Health Care | CA$9.3B | CA$259.6B | CA$149.89 | 2.55% down | 17% down | ||
| 12 | Regeneron PharmaceuticalsREGN · Health Care | CA$6.4B | CA$141B | CA$1,362.96 | 0.59% down | 36% up | ||
| 13 | AbbVieABBV · Health Care | CA$6B | CA$733.5B | CA$414.99 | 1.01% down | 26% up | ||
| 14 | Vertex PharmaceuticalsVRTX · Health Care | CA$5.7B | CA$193B | CA$761.13 | 0.47% down | 27% up | ||
| 15 | ZoetisZTS · Health Care | CA$3.8B | CA$47.9B | CA$117.90 | 1.34% down | 29% down | ||
| 16 | Teva Pharmaceutical IndustriesTEVA · Health Care | CA$2B | CA$71.6B | CA$61.37 | 0.62% up | 74% up | ||
| 17 | United TherapeuticsUTHR · Health Care | CA$1.9B | CA$35.5B | CA$832.76 | 0.40% down | 23% up | ||
| 18 | GenmabGMAB · Health Care | CA$1.4B | CA$45.5B | CA$73.82 | 0.75% down | 70% up | ||
| 19 | Royalty PharmaRPRX · Health Care | CA$1.1B | CA$56.3B | CA$97.95 | 0.37% down | 78% up | ||
| 20 | PTC TherapeuticsPTCT · Health Care | CA$977.2M | CA$7.2B | CA$85.69 | 0.83% down | 20% down | ||
| 21 | Dr. Reddy's LaboratoriesRDY · Health Care | CA$652.7M | CA$17.6B | CA$21.14 | 0.20% down | 5% up | ||
| 22 | TG TherapeuticsTGTX · Health Care | CA$640.1M | CA$13.5B | CA$89.40 | 0.41% down | 107% up | ||
| 23 | GrifolsGRFS · Health Care | CA$638.5M | CA$8.3B | CA$12.27 | 0.70% down | 1% up | ||
| 24 | BioMarin PharmaceuticalBMRN · Health Care | CA$499.4M | CA$16.2B | CA$83.44 | 0.38% down | 11% up | ||
| 25 | Alnylam PharmaceuticalsALNY · Health Care | CA$449.1M | CA$29.8B | CA$222.67 | 0.61% down | 66% down | ||
| 26 | BeOne MedicinesONC · Health Care | CA$410.7M | CA$66.5B | CA$582.30 | 1.57% down | 17% up | ||
| 27 | AlkermesALKS · Health Care | CA$345.9M | CA$11B | CA$65.29 | 0.35% up | 58% up | ||
| 28 | Ligand PharmaceuticalsLGND · Health Care | CA$178.2M | CA$8.5B | CA$424.10 | 0.84% up | 43% up | ||
| 29 | Corcept TherapeuticsCORT · Health Care | CA$142.6M | CA$11.1B | CA$101.33 | 1.02% up | 8% down | ||
| 30 | Amneal PharmaceuticalsAMRX · Health Care | CA$103.1M | CA$10.5B | CA$30.23 | 0.00% | 83% up | ||
| 31 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | CA$84.5M | CA$10.7B | CA$135.64 | 0.37% down | 126% up | ||
| 32 | Arrowhead PharmaceuticalsARWR · Health Care | -CA$2.3M | CA$8.7B | CA$61.24 | 0.49% down | 10% up | ||
| 33 | Mirum PharmaceuticalsMIRM · Health Care | -CA$33.4M | CA$8.6B | CA$131.02 | 0.46% down | 31% up | ||
| 34 | Travere TherapeuticsTVTX · Health Care | -CA$36.6M | CA$7B | CA$72.50 | 0.89% down | 44% up | ||
| 35 | VeradermicsMANE · Health Care | -CA$100.2M | CA$7.6B | CA$181.03 | 0.46% up | 233% up | ||
| 36 | Belite BioBLTE · Health Care | -CA$111.1M | CA$9.2B | CA$225.77 | 0.00% | 31% up | ||
| 37 | Oruka TherapeuticsORKA · Health Care | -CA$150.9M | CA$9.3B | CA$137.31 | 0.42% down | 241% up | ||
| 38 | ErascaERAS · Health Care | -CA$178.3M | CA$7B | CA$19.98 | 0.50% up | 403% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | -CA$186.3M | CA$11.6B | CA$178.28 | 0.10% down | 46% up | ||
| 40 | Spyre TherapeuticsSYRE · Health Care | -CA$222.2M | CA$12.8B | CA$134.83 | 0.41% up | 286% up | ||
| 41 | Dianthus TherapeuticsDNTH · Health Care | -CA$232.4M | CA$6.9B | CA$121.80 | 2.17% down | 113% up | ||
| 42 | Edgewise TherapeuticsEWTX · Health Care | -CA$240.2M | CA$6.6B | CA$60.55 | 0.62% up | 88% up | ||
| 43 | Axsome TherapeuticsAXSM · Health Care | -CA$262.2M | CA$10.3B | CA$195.40 | 0.40% up | 7% down | ||
| 44 | Definium TherapeuticsDFTX · Health Care | -CA$263.1M | CA$5.7B | CA$41.80 | 0.61% down | 169% up | ||
| 45 | Rhythm PharmaceuticalsRYTM · Health Care | -CA$281.3M | CA$11.5B | CA$165.65 | 0.76% down | 13% up | ||
| 46 | Elanco Animal HealthELAN · Health Care | -CA$332.1M | CA$18.5B | CA$36.95 | 0.15% down | 20% up | ||
| 47 | Ascendis PharmaASND · Health Care | -CA$362.2M | CA$25.2B | CA$384.30 | 1.00% down | 28% up | ||
| 48 | Madrigal PharmaceuticalsMDGL · Health Care | -CA$412.7M | CA$14B | CA$602.83 | 0.20% down | 24% down | ||
| 49 | Legend BiotechLEGN · Health Care | -CA$424.9M | CA$4.5B | CA$23.12 | 0.25% up | 42% down | ||
| 50 | Roivant SciencesROIV · Health Care | -CA$429.1M | CA$40.1B | CA$55.31 | 0.18% down | 90% up | ||
| 51 | Praxis Precision MedicinesPRAX · Health Care | -CA$434.1M | CA$12.2B | CA$436.00 | 0.16% down | 61% up | ||
| 52 | Cogent BiosciencesCOGT · Health Care | -CA$470.9M | CA$7B | CA$40.27 | 1.01% up | 20% down | ||
| 53 | Jazz PharmaceuticalsJAZZ · Health Care | -CA$509.8M | CA$22.1B | CA$343.70 | 0.25% down | 37% up | ||
| 54 | ABIVAXABVX · Health Care | -CA$533.8M | CA$10.4B | CA$118.81 | 1.10% up | 27% down | ||
| 55 | Ionis PharmaceuticalsIONS · Health Care | -CA$545.9M | CA$6.4B | CA$38.30 | 0.76% down | 64% down | ||
| 56 | BridgeBio PharmaBBIO · Health Care | -CA$1B | CA$21.3B | CA$109.51 | 0.39% down | 17% up | ||
| 57 | CytokineticsCYTK · Health Care | -CA$1.1B | CA$10.3B | CA$74.29 | 0.48% up | 20% down | ||
| 58 | Takeda PharmaceuticalTAK · Health Care | -CA$1.4B | CA$98.1B | CA$30.72 | 0.85% down | 54% up | ||
| 59 | Summit TherapeuticsSMMT · Health Care | -CA$1.5B | CA$11.9B | CA$14.88 | 2.58% down | 36% down | ||
| 60 | InsmedINSM · Health Care | -CA$1.8B | CA$38B | CA$173.21 | 0.71% down | 40% down | ||
| 61 | ViatrisVTRS · Health Care | -CA$5B | CA$33.6B | CA$29.35 | 0.24% up | 96% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Earnings is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 1.4315 CAD).
Questions and answers
Which pharmaceuticals rank first by earnings?
Johnson & Johnson (CA$38.4B), Eli Lilly (CA$29.5B) and Merck & Co (CA$26.1B) are the top three of the 61 pharmaceuticals ranked by earnings as of 18 Nov 2026, 14:31 UTC.
How many pharmaceuticals are in this ranking?
61 are ranked by earnings.
What are these pharmaceuticals worth together?
The 61 pharmaceuticals ranked by earnings have a combined market value of CA$7.32T as of 18 Nov 2026, 14:31 UTC.
What does ranking by earnings measure?
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceuticals by earnings”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=earnings
Underlying data: Yahoo Finance; SEC EDGAR.